416 related articles for article (PubMed ID: 18668535)
1. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.
Hoffman HM; Throne ML; Amar NJ; Sebai M; Kivitz AJ; Kavanaugh A; Weinstein SP; Belomestnov P; Yancopoulos GD; Stahl N; Mellis SJ
Arthritis Rheum; 2008 Aug; 58(8):2443-52. PubMed ID: 18668535
[TBL] [Abstract][Full Text] [Related]
2. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.
Goldbach-Mansky R; Shroff SD; Wilson M; Snyder C; Plehn S; Barham B; Pham TH; Pucino F; Wesley RA; Papadopoulos JH; Weinstein SP; Mellis SJ; Kastner DL
Arthritis Rheum; 2008 Aug; 58(8):2432-42. PubMed ID: 18668591
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.
Hoffman HM; Throne ML; Amar NJ; Cartwright RC; Kivitz AJ; Soo Y; Weinstein SP
Clin Ther; 2012 Oct; 34(10):2091-103. PubMed ID: 23031624
[TBL] [Abstract][Full Text] [Related]
4. Rilonacept in the treatment of chronic inflammatory disorders.
McDermott MF
Drugs Today (Barc); 2009 Jun; 45(6):423-30. PubMed ID: 19649332
[TBL] [Abstract][Full Text] [Related]
5. Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS).
Gillespie J; Mathews R; McDermott MF
J Inflamm Res; 2010; 3():1-8. PubMed ID: 22096352
[TBL] [Abstract][Full Text] [Related]
6. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.
Schumacher HR; Sundy JS; Terkeltaub R; Knapp HR; Mellis SJ; Stahl N; Yancopoulos GD; Soo Y; King-Davis S; Weinstein SP; Radin AR;
Arthritis Rheum; 2012 Mar; 64(3):876-84. PubMed ID: 22223180
[TBL] [Abstract][Full Text] [Related]
7. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS).
Hoffman HM
Expert Opin Biol Ther; 2009 Apr; 9(4):519-31. PubMed ID: 19344287
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study.
Krause K; Weller K; Stefaniak R; Wittkowski H; Altrichter S; Siebenhaar F; Zuberbier T; Maurer M
Allergy; 2012 Jul; 67(7):943-50. PubMed ID: 22583335
[TBL] [Abstract][Full Text] [Related]
9. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
[TBL] [Abstract][Full Text] [Related]
10. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.
Sundy JS; Schumacher HR; Kivitz A; Weinstein SP; Wu R; King-Davis S; Evans RR
J Rheumatol; 2014 Aug; 41(8):1703-11. PubMed ID: 25028379
[TBL] [Abstract][Full Text] [Related]
11. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial.
Hashkes PJ; Spalding SJ; Giannini EH; Huang B; Johnson A; Park G; Barron KS; Weisman MH; Pashinian N; Reiff AO; Samuels J; Wright DA; Kastner DL; Lovell DJ
Ann Intern Med; 2012 Oct; 157(8):533-41. PubMed ID: 23070486
[TBL] [Abstract][Full Text] [Related]
12. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
Koné-Paut I; Galeotti C
Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
[TBL] [Abstract][Full Text] [Related]
13. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.
Klein AL; Imazio M; Cremer P; Brucato A; Abbate A; Fang F; Insalaco A; LeWinter M; Lewis BS; Lin D; Luis SA; Nicholls SJ; Pano A; Wheeler A; Paolini JF;
N Engl J Med; 2021 Jan; 384(1):31-41. PubMed ID: 33200890
[TBL] [Abstract][Full Text] [Related]
14. Use of canakinumab in the cryopyrin-associated periodic syndrome.
Lachmann HJ; Kone-Paut I; Kuemmerle-Deschner JB; Leslie KS; Hachulla E; Quartier P; Gitton X; Widmer A; Patel N; Hawkins PN;
N Engl J Med; 2009 Jun; 360(23):2416-25. PubMed ID: 19494217
[TBL] [Abstract][Full Text] [Related]
15. Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap).
Church LD; Savic S; McDermott MF
Biologics; 2008 Dec; 2(4):733-42. PubMed ID: 19707454
[TBL] [Abstract][Full Text] [Related]
16. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
[TBL] [Abstract][Full Text] [Related]
17. Cryopyrin-associated periodic syndromes: background and therapeutics.
Kubota T; Koike R
Mod Rheumatol; 2010 Jun; 20(3):213-21. PubMed ID: 20140476
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
Landmann EC; Walker UA
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
[TBL] [Abstract][Full Text] [Related]
19. [Cryopyrin-associated periodic syndromes].
Quartier P; Rodrigues F; Georgin-Lavialle S
Rev Med Interne; 2018 Apr; 39(4):287-296. PubMed ID: 29111302
[TBL] [Abstract][Full Text] [Related]
20. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.
Terkeltaub R; Sundy JS; Schumacher HR; Murphy F; Bookbinder S; Biedermann S; Wu R; Mellis S; Radin A
Ann Rheum Dis; 2009 Oct; 68(10):1613-7. PubMed ID: 19635719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
